Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes. Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management.

Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes.

Risk Statement

Training is essential and must be completed before a patient starts using the Omnipod 5 System. As part of this process, you will need to meet with your patient to initiate and adjust their settings. They must also visit omnipod.com/setup to complete setup and schedule their required training. Omnipod 5 System Overview for HCPs: https://insulet.wistia.com/medias/jli756jpqx

Omnipod 5 for HCPs: https://www.omnipod.com/hcp/products/omnipod5

The Omnipod 5 Automated Insulin Delivery (AID) System is cleared for individuals with type 1 diabetes ages 2 and older & type 2 diabetes ages 18 and older. The Omnipod 5 System is intended for single patient, home use and requires a valid prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery User Guide and omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. To use Omnipod 5 in Automated Mode, the Dexcom G6 or Dexcom G7 mobile app is required. The Dexcom G6 or Dexcom G7 are not included in the Omnipod 5 System and require a separate prescription. The Dexcom G6 and G7 receivers are not compatible.